)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Allurion Technologies
Allurion Technologies (ALUR) investor relations material
Allurion Technologies has been otc
Allurion Technologies Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary15 May, 2026
Executive summary
Revenue for Q1 2026 was $2.9M, down 47% year-over-year, with a net loss of $6.1M compared to $1.5M in Q1 2025.
FDA approved the Allurion Gastric Balloon System in February 2026, expanding U.S. market potential.
The company faces ongoing liquidity challenges, with $5.1M in cash and substantial doubt about its ability to continue as a going concern.
Trading of common stock was suspended on the NYSE in March 2026 due to non-compliance with listing standards; shares now trade on the OTCQB Market.
Financial highlights
Gross profit fell 70% to $1.2M, driven by lower sales and higher inventory charges.
Operating expenses decreased 57% to $5.0M, reflecting restructuring and cost reductions.
Cash used in operations was $3.2M in Q1 2026, with $2.9M raised from a warrant inducement transaction.
Accumulated deficit reached $257.1M as of March 31, 2026.
Outlook and guidance
Management expects continued operating losses and negative cash flows, with additional capital needed to fund operations.
Strategic focus is on regulatory approvals, commercialization, and cost management.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Allurion Technologies
- 2025 revenue dropped 53% to $15.2M; net loss $28.8M; FDA approval gained, but going concern risk remains.ALUR
Q4 2025 - Up to 5,988,024 shares registered for resale, with $5M potential proceeds from warrant exercises.ALURRegistration Filing
- Shelf registration for up to $100M supports global obesity platform expansion amid high risks.ALURRegistration Filing
- Q3 revenue dropped 71% as AI sales soared and restructuring targets 2025 profitability.ALURQ3 2024
- Q2 revenue up 25% sequentially, but France suspension and NYSE risks weigh on outlook.ALURQ2 2024
- Innovative weight loss balloon and digital platform fuel growth, with U.K. reimbursement and U.S. expansion.ALURJefferies 2024 Global Healthcare Conference
- Innovative gastric balloon and digital platform target obesity with strong growth and U.S. expansion ahead.ALURSmall-Cap Growth Virtual Investor Conference
- Allurion pivots to B2B2C, cuts costs, and eyes FDA approval for US launch in 2026.ALURTD Cowen 45th Annual Healthcare Conference
- 2024 revenue reached $32.1M, with cost cuts and growth in GLP-1 combination therapy.ALURQ4 2024
Allurion Technologies
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Allurion Technologies Inc. is a healthcare company operating in the medical devices industry, primarily focused on combating obesity. The company's flagship offering is the Allurion Program, a comprehensive weight loss platform that includes the Allurion Balloon, a novel, swallowable, and procedure-less intragastric balloon designed to facilitate weight loss. Beyond the balloon, Allurion provides an integrated suite of digital health tools for both patients and healthcare providers, including the Allurion Virtual Care Suite, which features AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth services. These offerings aim to customize, monitor, and manage weight loss therapy for patients, irrespective of their specific treatment plan. Allurion Technologies Inc. is headquartered in Natick, Massachusetts, and its shares are listed on the New York Stock Exchange.